Buparlisib plus carboplatin or lomustine in patients with recurrent glioblastoma: a phase Ib/II, open-label, multicentre, randomised study

authors

  • Rosenthal Mark
  • Clement Paul
  • Campone Mario
  • Gil-Gil Miguel
  • Degroot John
  • Chinot Olivier
  • Idbaih Ahmed
  • Gan Hui
  • Raizer Jeffrey
  • Wen Patrick Yung
  • Pineda Estela
  • Donnet Valerie
  • Mills David
  • El-Hashimy Mona
  • Mason Warren

keywords

  • BKM120
  • Buparlisib
  • RGBM
  • Recurrent glioblastoma

document type

ART

abstract

Glioblastoma relapse is associated with activation of phosphatidylinositol 3-kinase (PI3K) signalling pathway. In preclinical studies, the pan-PI3K inhibitor buparlisib showed antitumour activity in glioma models.

more information